Abeera Ali, MD
Neurology · Oklahoma City, OKNPI 1699150409
Payments from drug & device makers
Across 160 payments — averaging $16.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- GE HealthCare$176
- Pfizer$141
- Novartis$135
- Teva Pharmaceuticals USA, Inc.$116
- UCB, Inc.$116
- plus $922 from 25 others
What the payments were for
- Food & beverage$2,618100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 80 | $1,011 |
| GE HealthCare | 8 | $176 |
| Pfizer | 7 | $141 |
| Novartis | 7 | $135 |
| Teva Pharmaceuticals USA, Inc. | 6 | $116 |
| UCB, Inc. | 6 | $116 |
| Lilly USA, LLC | 5 | $84 |
| Argenx US, Inc. | 4 | $84 |
| Livanova USA, Inc. | 2 | $77 |
| Biogen | 3 | $61 |
| Lundbeck LLC | 2 | $59 |
| Eisai Inc. | 2 | $56 |
| TG Therapeutics, Inc. | 2 | $53 |
| Amneal Pharmaceuticals LLC | 3 | $53 |
| Neurocrine Biosciences, Inc. | 3 | $48 |
| Avion Pharmaceuticals | 2 | $46 |
| Bristol Myers Squibb | 2 | $34 |
| Ipsen Biopharmaceuticals, Inc | 1 | $34 |
| Corium, LLC | 1 | $28 |
| SK Life Science, Inc. | 1 | $26 |
| Sanofi | 1 | $23 |
| Alnylam Pharmaceuticals Inc. | 1 | $23 |
| Mallinckrodt Enterprises LLC | 1 | $22 |
| Genentech USA, Inc. | 1 | $20 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $17 |
| AstraZeneca | 1 | $16 |
| Acadia Pharmaceuticals Inc | 1 | $14 |
| Averitas Pharma Inc. | 1 | $14 |
| Sunovion Pharmaceuticals Inc. | 2 | $14 |
| E.r. Squibb & Sons, L.L.C. | 1 | $11 |
| Sumitomo Pharma America, Inc. | 2 | $5 |
How this compares
$2,618 in reported general payments places this provider in the 50th percentile of 152 neurology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Emgality PenGalcanezumab-Gnlm | 36 | $23,957 |
| Rivastigmine | 71 | $10,695 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 218 | $6,265 |
| Memantine Hcl | 229 | $5,150 |
| Lamotrigine ErLamotrigine | 13 | $4,922 |
| RivastigmineRivastigmine Tartrate | 76 | $4,536 |
| Levetiracetam | 88 | $4,164 |
| Carbamazepine ErCarbamazepine | 21 | $3,735 |
| Donepezil Hcl | 427 | $3,456 |
| Rufinamide | 12 | $2,775 |
| Sumatriptan Succinate | 25 | $2,411 |
| Oxcarbazepine | 18 | $2,296 |
| Gabapentin | 160 | $2,240 |
| Propranolol Hcl ErPropranolol Hcl | 48 | $1,841 |
| Lacosamide | 31 | $1,624 |
Paid to pharmacies, not to this prescriber.
Other neurology in Oklahoma City
- Gabriel PardoOklahoma City$10.3M
- Cherian KarunapuzhaOklahoma City$4.1M
- James BattisteOklahoma City$1.1M
- Mariana VargaOklahoma City$670K
- Marguerite ButcheeOklahoma City$324K
- Chelsea BerkleyOklahoma City$277K
- Evgeny SidorovOklahoma City$212K
- Aaron FarrowOklahoma City$172K
- Ashish MasihOklahoma City$168K
- Erika Santos HortaOklahoma City$93K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.